Effect of MePEG molecular weight and particle size on in vitro release of tumor necrosis factor-α-loaded nanoparticles

被引:16
作者
Fang, C [1 ]
Shi, B [1 ]
Pei, YY [1 ]
机构
[1] Fudan Univ, Sch Pharm, Dept Pharmaceut, Shanghai 200032, Peoples R China
关键词
tumor necrosis factor-alpha; stealth nanoparticles; polyethylene glycols; poly(methoxypolyethyleneglycol cyanoacrylate-co-n-hexadecyl cyanoacrylate);
D O I
10.1111/j.1745-7254.2005.00537.x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: To study the in vitro release of recombinant human tumor necrosis factor-alpha (rHuTNF-alpha) encapsulated in poly (methoxypolyethyleneglycol cyanoacrylate-co-n-hexadecyl cyanoacrylate) (PEG-PHDCA) nanoparticles, and investigate the influence of methoxypolyethyleneglycol (MePEG) molecular weight and particle size. Methods: Three sizes (approximately 80, 170, and 240 nm) of PEG-PHDCA nanoparticles loading rHuTNF-a were prepared at different MePEG molecular weights (M-r =2000, 5000, and 10 000) using the double emulsion method. The in vitro rHuTNF-alpha release was studied in PBS and rat plasma. Results: A higher burst-release and cumulative-release rate were observed for nanoparticles with higher MePEG molecular weight or smaller particle size. A decreased cumulative release of rHuTNF-alpha following the initial burst effect was found in PBS, while the particle sizes remained constant and MePEG liberated. In contrast, in rat plasma, slowly increased cumulative-release profiles were obtained after the burst effect. During a 5-h incubation in rat plasma, more than 50% of the PEG-PHDCA nanoparticles degraded. Conclusion: The MePEG molecular weight and particle size had an obvious influence on rHuTNF-alpha release. rHuTNF-alpha released from PEG-PHDCA nanoparticles in a diffusion-based pattern in PBS, but in a diffusion and erosion-controlled manner in rat plasma.
引用
收藏
页码:242 / 249
页数:8
相关论文
共 22 条
[1]   PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in Vivo drug residence in blood properties [J].
Avgoustakis, K ;
Beletsi, A ;
Panagi, Z ;
Klepetsanis, P ;
Karydas, AG ;
Ithakissios, DS .
JOURNAL OF CONTROLLED RELEASE, 2002, 79 (1-3) :123-135
[2]   Near infrared with principal component analysis as a novel analytical approach for nanoparticle technology [J].
Brigger, I ;
Chaminade, P ;
Desmaële, D ;
Peracchia, MT ;
d'Angelo, J ;
Gurny, R ;
Renoir, M ;
Couvreur, P .
PHARMACEUTICAL RESEARCH, 2000, 17 (09) :1124-1132
[3]   Nanoparticles in cancer therapy and diagnosis [J].
Brigger, I ;
Dubernet, C ;
Couvreur, P .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) :631-651
[4]   In vitro cell interaction and in vivo biodistribution of poly(lactide-co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers [J].
Dunn, SE ;
Coombes, AGA ;
Garnett, MC ;
Davis, SS ;
Davies, MC ;
Illum, L .
JOURNAL OF CONTROLLED RELEASE, 1997, 44 (01) :65-76
[5]   Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system [J].
Gaur, U ;
Sahoo, SK ;
De, TK ;
Ghosh, PC ;
Maitra, A ;
Ghosh, PK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 202 (1-2) :1-10
[6]  
Li YP, 2001, ACTA PHARMACOL SIN, V22, P645
[7]   Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-α carriers:: Pharmacokinetics and anti-tumor effects [J].
Li, YP ;
Pei, YY ;
Zhou, ZH ;
Zhang, XY ;
Gu, ZH ;
Ding, J ;
Zhou, JJ ;
Gao, XJ ;
Zhu, JH .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2001, 24 (06) :662-665
[8]   PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-α carriers [J].
Li, YP ;
Pei, YY ;
Zhou, ZH ;
Zhang, XY ;
Gu, ZH ;
Ding, J ;
Zhou, JJ ;
Gao, XJ .
JOURNAL OF CONTROLLED RELEASE, 2001, 71 (03) :287-296
[9]   PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats [J].
Li, YP ;
Pei, YY ;
Zhang, XY ;
Gu, ZH ;
Zhou, ZH ;
Yuan, WF ;
Zhou, JJ ;
Zhu, JH ;
Gao, XJ .
JOURNAL OF CONTROLLED RELEASE, 2001, 71 (02) :203-211
[10]   Stability and release performance of a series of pegylated copolymeric micelles [J].
Lin, WJ ;
Juang, LW ;
Lin, CC .
PHARMACEUTICAL RESEARCH, 2003, 20 (04) :668-673